Effect of ruboxistaurin (RBX) on visual acuity decline over a 6-year period with cessation and reinstitution of therapy: Results of an open-label extension of the protein kinase C diabetic retinopathy study 2 (PKC-DRS2)

Retina

Volumn 31, Issue 6, 2011, Pages 1053-1059

  Sheetz, Matthew J ^a   Aiello, Lloyd Paul ^b   Shahri, Nazila ^c   Davis, Matthew D ^d   Kles, Keri A ^a   Danis, Ronald P ^d  

^a ELI LILLY AND COMPANY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c I3 Statprobe   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

diabetes; diabetic retinopathy; open label extension; Ruboxistaurin; sustained moderate visual loss

Indexed keywords

PLACEBO; PROTEIN KINASE C; RUBOXISTAURIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CELLULITIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; DYSPNEA; EARLY TREATMENT DIABETIC RETINOPATHY STUDY CHART; FEMALE; HEART INFARCTION; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; OSTEOMYELITIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADMINISTRATION, ORAL; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; MALE; MALEIMIDES; MIDDLE AGED; PROTEIN KINASE C; RETREATMENT; VISION DISORDERS; VISION TESTS; VISUAL ACUITY; WITHHOLDING TREATMENT;

EID: 79958295090     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181fe545f     Document Type: Article

References (19)

1. Kempen JH, O'Colmain BJ, Leske MC, et al; Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-563. (Pubitemid 38456292)
2. Centers for Disease Control and Prevention (CDC). Blindness caused by diabetes\Massachusetts, 1987-1994. MMWR Morb Mortal Wkly Rep 1996;45:937-941.
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-986.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylurease or insulin com-pared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853.
5. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complication in type 2 diabetes: UKPDS 38. BMJ 1998;317: 703-713.
6. Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976;81:383-396.
7. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991;98:766-785.
8. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806.
9. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trail: Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol 1985; 103:1644-1652.
10. Klein R, Klein BE, Moss SE, de la Cuesta FS. The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabetes Metab Rev 1989;5:559-570. (Pubitemid 19272666)
11. De La Cruz JP, Gonzalez-Correa JA, Guerrero A, et al. Pharmacological approach to diabetic retinopathy. Diabetes Metab Res Rev 2004;20:91-113.
12. Suzuma K, Takahara N, Suzuma I, et al. Characterization of protein kinase C ß isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA 2002;99:721-726. (Pubitemid 34106577)
13. Ishii H, Koya D, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1997;76:21-31.
14. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98:2018-2026. (Pubitemid 26376289)
15. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective ß-isoform-selective inhibitor. Diabetes 1997;46:1473-1480. (Pubitemid 27369086)
16. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC ß inhibitor. Science 1996;272:728-731. (Pubitemid 26000279)
17. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC ß inhibition with LY333531. Invest Ophthalmol Vis Sci 1998;39:171-179. (Pubitemid 28040476)
18. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC ß by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006;47:86-92. (Pubitemid 46780799)
19. The PKC-DRS2 Study Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221-2230.